Physician profile
William E Cooke
NPI 1699749770
$76,369.12
in general payments reported to CMS, 2019-2025
33 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $10K · 2021: $3,988 · 2022: $160 · 2023: $683 · 2024: $5,237 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $3,938 · Travel and Lodging: $2,688 · Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,700.00 |
| Consulting Fee | $3,937.50 |
| Travel and Lodging | $2,688.24 |
| Food and Beverage | $2,381.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $50,657.02 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $22,783.15 | 2019-2025 | Vraylar, Mavyret |
| Glaxosmithkline, LLC. | $1,284.62 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $282.07 | 2019-2020 | |
| Gilead Sciences, INC. | $269.86 | 2019-2023 | |
| Novo Nordisk INC | $199.96 | 2019-2021 | |
| Alkermes, INC. | $81.82 | 2019-2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $76.68 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $73.12 | 2019-2024 | Delstrigo, Isentress, Pifeltro |
| Amgen INC. | $64.90 | 2019-2022 | |
| Emd Serono, INC. | $51.39 | 2025 | Serostim |
| Otsuka America Pharmaceutical, INC. | $48.47 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $45.81 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $44.77 | 2019-2020 | |
| Pfizer INC. | $42.32 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.07 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $35.32 | 2023-2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.88 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $27.88 | 2023 | Mounjaro |
| Indivior INC. | $26.06 | 2020-2024 | Sublocade |
| Tris Pharma INC | $21.48 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $18.59 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.94 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.28 | 2025 | Jornay Pm |
| Medtronic, INC. | $17.13 | 2025 | Minimed 780g |
| Medline Industries Lp | $16.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.87 | 2025 | |
| Ironshore Pharmaceuticals INC. | $15.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2020 | |
| Amarin Pharma, INC. | $14.48 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2019 | |
| Janssen Biotech, INC. | $12.80 | 2019 | |
| Abbott Laboratories | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.